Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
Impact · McMaster University · +47 more institutions
Abstract
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed.
We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations.
Citation impact
- FWCI
- 36.01
- Percentile
- 100%
- References
- 534
Authors
36- WAWaleed AlhazzaniCorresponding
Impact, McMaster University
- MHMorten Hylander Møller
Society of Critical Care Medicine, Copenhagen University Hospital, Rigshospitalet
- YMYaseen M. Arabi
King Saud bin Abdulaziz University for Health Sciences, Advisory Board Company (United States), King Abdullah International Medical Research Center, National Guard Health Affairs
- MLMark Loeb
Impact, McMaster University
- MNMichelle N. Gong
Albert Einstein College of Medicine, Montefiore Health System
Topics & keywords
- Medicine
- Intensive care medicine
- MEDLINE
- Health care
- Critically ill
- Grading (engineering)
- Intensive care
- Coronavirus disease 2019 (COVID-19)